ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1025

Prevalence Estimates for Systemic Lupus Erythematosus over Four Decades

Ali Duarte-Garcia1, Mehmet Hocaoglu2, Shirley-Ann Osei-Onomah3, Jesse Dabit1, Sara J. Achenbach3 and Cynthia Crowson4, 1Mayo Clinic, Rochester, MN, 2University of Maryland Medical Center Midtown Campus, Baltimore, MD, 3Mayo Clinic, Rochester, 4Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

Meeting: ACR Convergence 2020

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Prevalence estimates of disease are important for public health planning. The available prevalence estimates of systemic lupus erythematosus (SLE) do not account for changes in exposures or survival that may contribute to prevalence changes over time. We aimed to estimate the prevalence of SLE over four decades.

Methods: Using established population-based research infrastructure that links the medical records of all the individuals in a geographically well-defined population, we identified all the prevalent SLE cases from 1976 through 2018 using diagnostic codes for cutaneous and systemic lupus and the following laboratory measures: anti-nuclear antibodies, anti-double stranded DNA, anti-Sm, anti-cardiolipin, anti-beta 2 glycoprotein 1antibodies, complement levels, coombs and lupus anticoagulant. Given that patients may migrate to our region after the diagnosis of SLE and might had longstanding disease, we classified prevalent cases if the treating rheumatologist or nephrologist had a statement confirming SLE diagnosis in the medical record.

We estimated point prevalence for January 1 of the years 1985, 1995, 2005 and 2015. Only individuals who were residents of our region for at least a year were included in the analysis.

Prevalence rates were age‐ and/or sex‐adjusted to the estimated 2010 white population of the US. To compute 95% confidence intervals for prevalence rates, it was assumed that the number of prevalent cases followed a Poisson distribution.

Results: We identified 46 prevalent cases in 1985, 63 in 1995, 92 in 2005 and 131 in 2015. As detailed in Table 1 the mean age of prevalent cases over four decades increased from 47.3 years in 1985 to 54.6 years in 2015. Race was reported consistently from 1995 onwards, the proportion of whites decreased from 95% to 82% while the proportion of males increased from 9% to 17%.

Overall, from 1985 to 2015 the prevalence increased by 64%; 55.2 per 100,000 in 1985 to 90.8 per 100,000 in 2015. In females the prevalence increased by 44% from 100.6 to 144.9 per 100,000, while in males it increased 360% from 7.3 to 33.6 per 100,000 (Table 2).

Conclusion: Results from the study show a dramatic increase in prevalence of SLE in the last four decades. These trends likely reflect improvements in survival. The biggest gains have been on the male SLE patients. It is unclear if other factors, such as an increase in SLE incidence or changes in the racial composition of the population are influencing these epidemiologic changes.

Table 1. Prevalence Cohorts of Lupus Demographic Characteristics

Table 2 Prevalence rates of systemic lupus erythematosus over four decades


Disclosure: A. Duarte-Garcia, None; M. Hocaoglu, None; S. Osei-Onomah, None; J. Dabit, None; S. Achenbach, None; C. Crowson, Myriad Genetics, 1, Pfizer, 1.

To cite this abstract in AMA style:

Duarte-Garcia A, Hocaoglu M, Osei-Onomah S, Dabit J, Achenbach S, Crowson C. Prevalence Estimates for Systemic Lupus Erythematosus over Four Decades [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/prevalence-estimates-for-systemic-lupus-erythematosus-over-four-decades/. Accessed September 22, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-estimates-for-systemic-lupus-erythematosus-over-four-decades/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology